The continuing role of PSA in the detection and management of prostate cancer
(2007) In European Urology. Supplement 6(3). p.327-333- Abstract
- Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specific antigen (PSA) testing remains controversial. Doubts have been raised over the continued use of PSA in the detection of clinically significant prostate cancer because many men now present with early-stage, small-volume tumours. This article examines the limitations of using a single PSA value in diagnosis and discusses alternative approaches to PSA testing, in particular PSA velocity and PSA doubling time, which are now emerging as valuable pretreatment disease predictors. A clinical scenario is also presented to illustrate the use of PSA kinetics in identifying candidates for biopsy. (c) 2006 European Association of Urology. Published by... (More)
- Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specific antigen (PSA) testing remains controversial. Doubts have been raised over the continued use of PSA in the detection of clinically significant prostate cancer because many men now present with early-stage, small-volume tumours. This article examines the limitations of using a single PSA value in diagnosis and discusses alternative approaches to PSA testing, in particular PSA velocity and PSA doubling time, which are now emerging as valuable pretreatment disease predictors. A clinical scenario is also presented to illustrate the use of PSA kinetics in identifying candidates for biopsy. (c) 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/674200
- author
- Miller, Kurt ; Abrahamsson, Per-Anders LU ; Akakura, Koichiro ; Debruyne, Frans M. J. ; Evans, Christopher P. and Klotz, Laurence
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- PSA doubling time, prostate cancer, PSA, PSA velocity
- in
- European Urology. Supplement
- volume
- 6
- issue
- 3
- pages
- 327 - 333
- publisher
- Elsevier
- external identifiers
-
- wos:000244379300002
- scopus:33846408703
- ISSN
- 1569-9056
- DOI
- 10.1016/j.eursup.2006.12.001
- language
- English
- LU publication?
- yes
- id
- 76e9754f-1af2-43ae-9b10-96ef2e4cd0c9 (old id 674200)
- date added to LUP
- 2016-04-01 17:04:59
- date last changed
- 2022-03-22 23:12:22
@article{76e9754f-1af2-43ae-9b10-96ef2e4cd0c9, abstract = {{Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specific antigen (PSA) testing remains controversial. Doubts have been raised over the continued use of PSA in the detection of clinically significant prostate cancer because many men now present with early-stage, small-volume tumours. This article examines the limitations of using a single PSA value in diagnosis and discusses alternative approaches to PSA testing, in particular PSA velocity and PSA doubling time, which are now emerging as valuable pretreatment disease predictors. A clinical scenario is also presented to illustrate the use of PSA kinetics in identifying candidates for biopsy. (c) 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved.}}, author = {{Miller, Kurt and Abrahamsson, Per-Anders and Akakura, Koichiro and Debruyne, Frans M. J. and Evans, Christopher P. and Klotz, Laurence}}, issn = {{1569-9056}}, keywords = {{PSA doubling time; prostate cancer; PSA; PSA velocity}}, language = {{eng}}, number = {{3}}, pages = {{327--333}}, publisher = {{Elsevier}}, series = {{European Urology. Supplement}}, title = {{The continuing role of PSA in the detection and management of prostate cancer}}, url = {{http://dx.doi.org/10.1016/j.eursup.2006.12.001}}, doi = {{10.1016/j.eursup.2006.12.001}}, volume = {{6}}, year = {{2007}}, }